PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Clinical and Molecular Hepatology10.3350/cmh.2012.18.3.2722012183272A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis CByung Chul You, Young Seok Kim, Hun il Kim, Se Hun Kim, Seung Sik Park, Yu Ri Seo, Sang Gyune Kim, Se Whan Lee, Hong Soo Kim, Soung Won Jeong, Jae Young Jang, Boo Sung Kimhttp://synapse.koreamed.org/pdf/10.3350/cmh.2012.18.3.272, http://synapse.koreamed.org/DOIx.php?id=10.3350/cmh.2012.18.3.272, http://www.e-cmh.org/upload/pdf/cmh-18-272.pdf
Gastroenterology10.1016/s0016-5085(19)40379-x20191566S-1344Tu1499 – Vitamin D Deficiency and Sustained Virologic Response on Antiviral Therapy with Pegylated Interferon Alpha 2 and Ribavirin in Patients with Chronic Hepatitis C, Genotype-1Elena Kukhareva, Olga Tarasova, Pavel Ogurtsovhttps://api.elsevier.com/content/article/PII:S001650851940379X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S001650851940379X?httpAccept=text/plain
Gastroenterology10.1016/s0016-5085(01)82822-520011205A568-A568Re-treatment virologic response in chronic hepatitis C virologic non-responders (NR) and responder-relapsers (NR) to interferon (IFN) monotherapy: IFN α-2b induction followed by combination ribavirin/interferon α-2b vs combination ribavirin/interferon α-2b (780 MIU/52 weeks rebetron therapy)N PIMSTONE, J CANIO, M CHIANG, J KOKOSINSKI, J POWELL, T SAICHEUR, P SHEYKHZADEH, A YUhttps://api.elsevier.com/content/article/PII:S0016508501828225?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508501828225?httpAccept=text/plain
Journal of Viral Hepatitis10.1111/j.1365-2893.2009.01099.x2009165346-351Impact of early viral kinetics on pegylated interferon alpha 2b plus ribavirin therapy in Japanese patients with genotype 2 chronic hepatitis CH. Nomura, Y. Miyagi, H. Tanimoto, H. Ishibashihttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2893.2009.01099.x, http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2893.2009.01099.x/fullpdf
Journal of Clinical Virology10.1016/s1386-6532(06)80455-5200636S147P.275 Influence of genotype, viral load and fibrosis on the sustained virologic response rate to pegylated interferon alpha-2a plus ribavirin, with or without amantadine, in chronic hepatitis C patients non-responders to alpha interferferon plus ribavirinH. Cheinquer, M. Pessoa, H. Sette, E. Parise, R. Paraná, F. Tatschhttps://api.elsevier.com/content/article/PII:S1386653206804555?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1386653206804555?httpAccept=text/plain
Journal of Hepatology10.1016/s0168-8278(01)80873-42001340237-257Pegylated interferon alpha 2B (peg IFN)_plus ribavirin (R) for the treatment of chronic hepatitis c: optimization fo ribavirin doseM Mannshttps://api.elsevier.com/content/article/PII:S0168-8278(01)80873-4?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0168-8278(01)80873-4?httpAccept=text/plain
Journal of Clinical Virology10.1016/s1386-6532(06)80456-7200636S147-S148P.276 Influence of genotype, viral load and fibrosis on the sustained virologic response rate to pegylated interferon alpha-2a plus ribavirin, with or without amantadine, in chronic hepatitis C patients relapsers to alpha interferferon plus ribavirinH. Cheinquer, H. Sette, M. Pessoa, R. Paraná, E. Parise, F. Tatschhttps://api.elsevier.com/content/article/PII:S1386653206804567?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1386653206804567?httpAccept=text/plain
Gastroenterology10.1016/s0016-5085(08)82822-320011205A568Re-treatment virologic response in chronic hepatitis C virologic non-responders (NR) and responder-relapsers (NR) to interferon (IFN) monotherapy: IFN α-2b induction followed by combination ribavirin/interferon α-2b vs combination ribavirin/interferon α-2b (780 MIU/52 weeks rebetron therapy)Neville R. Pimstone, John B. Canio, Michelle H. Chiang, Janet Kokosinski, Jerry S. Powell, Theparat Saicheur, Paul I. Sheykhzadeh, Andy S. Yuhttps://api.elsevier.com/content/article/PII:S0016508508828223?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508508828223?httpAccept=text/plain
Hepatology10.1016/0270-9139(95)94333-11995224A152Combination treatment of alpha interferon-2b (alpha IFN) and ribavirin in chronic hrpatitis C genotype 4 patients resistant to interferon therapyA ELZAYADIhttps://api.elsevier.com/content/article/PII:0270-9139(95)94333-1?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:0270-9139(95)94333-1?httpAccept=text/plain
Gastroenterology10.1016/s0016-5085(08)63892-520081344A-832-A-833W1016 Efficacy and Safety of Erythropoietin-Alfa On NaïVe Patients with Chronic Hepatitis C and Genotype 1 Receiving Combination Therapy with Pegylated Interferon-Alfa 2b and RibavirinDagmary Purcell, Doris H. Torohttps://api.elsevier.com/content/article/PII:S0016508508638925?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508508638925?httpAccept=text/plain